The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRCO, COCP and ABBV
NEW YORK, Sept. 23, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Tribune Media Company (NYSE: TRCO) Class Period: November 29, 2017 to July 16, 2018 Lead Plaintiff Deadline: November 13, 2018
The lawsuit alleges that Tribune made materially false and/or misleading statements and/or failed to disclose that: (1) Sinclair Broadcasting Group, Inc., which had agreed to merge with Tribune, was refusing to divest itself of television stations in certain markets necessary in order to secure regulatory approval; and (2) Sinclair was taking the position that it was not legally or contractually obligated to complete the identified divestitures to ensure regulatory approval.
Get additional information about the TRCO lawsuit: http://www.kleinstocklaw.com/pslra-1/tribune-media-company-loss-submission-form?wire=3
Cocrystal Pharma, Inc. f/k/a BioZone Pharmaceuticals, Inc. (NASDAQCM: COCP) Class Period: September 23, 2013 to September 7, 2018 Lead Plaintiff Deadline: November 19, 2018
The lawsuit alleges that Cocrystal Pharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC disclosure regulations; and (4) as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Get additional information about the COCP lawsuit: http://www.kleinstocklaw.com/pslra-1/cocrystal-pharma-inc-formerly-biozone-pharmaceuticals-inc-loss-submission-form?wire=3
AbbVie Inc. (NYSE: ABBV) Class Period: May 30, 2018 Lead Plaintiff Deadline: September 24, 2018
The complaint alleges that AbbVie issued false and misleading statements, in both press releases and filings with the U.S. Securities and Exchange Commission, regarding the results of the Company’s $7.5 billion modified Dutch auction tender offer that expired on May 29, 2018 (the “Tender Offer”). Specifically, the complaint alleges that before the opening of trading on May 30, 2018, the Company announced that it expected to acquire 71.4 million of its shares tendered at or below $105 per share. As a result of this news, the price of AbbVie securities significantly increased. However, after the close of trading on May 30, 2018, the Company released materially different results for the Tender Offer due to certain omissions, announcing that the Company expected to acquire only those shares tendered at or below $103 per share. Upon this news, AbbVie shares fell from a close of $103.01 per share on May 30, 2018, to a close of $98.94 on May 31, 2018.
Get additional information about the ABBV lawsuit: http://www.kleinstocklaw.com/pslra-c/abbvie-inc?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.